These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 20143131)
1. Modeling prostate cancer: a perspective on transgenic mouse models. Jeet V; Russell PJ; Khatri A Cancer Metastasis Rev; 2010 Mar; 29(1):123-42. PubMed ID: 20143131 [TBL] [Abstract][Full Text] [Related]
2. New prospectives of prostate cancer gene therapy: molecular targets and animal models. Hsieh CL; Chung LW Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967 [TBL] [Abstract][Full Text] [Related]
3. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. Kasper S J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647 [TBL] [Abstract][Full Text] [Related]
4. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. Kasper S; Smith JA J Urol; 2004 Jul; 172(1):12-9. PubMed ID: 15201729 [TBL] [Abstract][Full Text] [Related]
5. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Narayanan BA; Narayanan NK; Pittman B; Reddy BS Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007 [TBL] [Abstract][Full Text] [Related]
6. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
7. Transgenic mouse models for the prevention of breast cancer. Shen Q; Brown PH Mutat Res; 2005 Aug; 576(1-2):93-110. PubMed ID: 15888345 [TBL] [Abstract][Full Text] [Related]
8. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287 [TBL] [Abstract][Full Text] [Related]
9. Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model. Yoshidome K; Shibata MA; Maroulakou IG; Liu ML; Jorcyk CL; Gold LG; Welch VN; Green JE Int J Oncol; 1998 Feb; 12(2):449-53. PubMed ID: 9458374 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1. Abdulkadir SA Ann N Y Acad Sci; 2005 Nov; 1059():33-40. PubMed ID: 16382041 [TBL] [Abstract][Full Text] [Related]
11. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Perez-Stable C; Altman NH; Mehta PP; Deftos LJ; Roos BA Cancer Res; 1997 Mar; 57(5):900-6. PubMed ID: 9041192 [TBL] [Abstract][Full Text] [Related]
12. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735 [TBL] [Abstract][Full Text] [Related]
13. Models of metastatic prostate cancer: a transgenic perspective. Winter SF; Cooper AB; Greenberg NM Prostate Cancer Prostatic Dis; 2003; 6(3):204-11. PubMed ID: 12970722 [TBL] [Abstract][Full Text] [Related]
14. Androgen-independent prostate cancer progression in the TRAMP model. Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517 [TBL] [Abstract][Full Text] [Related]
16. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Garcia GE; Wisniewski HG; Lucia MS; Arevalo N; Slaga TJ; Kraft SL; Strange R; Kumar AP Clin Cancer Res; 2006 Feb; 12(3 Pt 1):980-8. PubMed ID: 16467113 [TBL] [Abstract][Full Text] [Related]
18. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097 [TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609 [TBL] [Abstract][Full Text] [Related]
20. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Gabril MY; Duan W; Wu G; Moussa M; Izawa JI; Panchal CJ; Sakai H; Xuan JW Mol Ther; 2005 Mar; 11(3):348-62. PubMed ID: 15727931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]